The overall ratings of seven Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Discovery Laboratories’ (NASDAQ:DSCO) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, DSCO also gets F’s. For more information, get Portfolio Grader’s complete analysis of DSCO stock.
Slipping from C to a D rating, Achillion (NASDAQ:ACHN) takes a hit this week. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of March 27, 2013, 15.8% of outstanding Achillion shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader.
The rating of Genomic Health (NASDAQ:GHDX) declines this week from C to a D. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock price has dropped 6.2% over the past month, worse than the 3.9% increase the Nasdaq has seen over the same period of time. The stock currently has a trailing PE Ratio of 111.60. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.
This week, Acorda Therapeutics’ (NASDAQ:ACOR) rating worsens to a D from the company’s C rating a week ago. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Amarin’s (NASDAQ:AMRN) rating weakens this week, dropping to a D versus last week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. The stock price has fallen 11.1% over the past month. As of March 27, 2013, 17.1% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.
Exelixis’ (NASDAQ:EXEL) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of March 27, 2013, 20.6% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.
Trius Therapeutics (NASDAQ:TSRX) is having a tough week. The company’s rating falls from C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
